4.7 Article

An in vitro screening cascade to identify neuroprotective antioxidants in ALS

期刊

FREE RADICAL BIOLOGY AND MEDICINE
卷 46, 期 8, 页码 1127-1138

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2009.01.019

关键词

Antioxidant; Amyotrophic lateral sclerosis; Mouse; NSC34; Superoxide dismutase; Free radicals

资金

  1. Wellcome Trust
  2. University of Sheffield

向作者/读者索取更多资源

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease, characterized by progressive dysfunction and death of motor neurons. Although evidence for oxidative stress in ALS pathogenesis is well described, antioxidants have generally shown poor efficacy in animal models and human clinical trials. We have developed an in vitro screening cascade to identify antioxidant molecules capable of rescuing NSC34 motor neuron cells expressing an ALS-associated mutation of superoxide disinutase 1. We have tested known antioxidants and screened a library of 2000 small molecules. The library screen identified 164 antioxidant molecules, which were refined to the 9 most promising molecules in subsequent experiments. Analysis of the in silico properties of hit compounds and a review of published literature on their in vivo effectiveness have enabled us to systematically identify molecules with antioxidant activity combined with chemical properties necessary to penetrate the central nervous system. The top-performing molecules identified include caffeic acid phenethyl ester, esculetin, and resveratrol. These compounds were tested for their ability to rescue primary motor neuron cultures after trophic factor withdrawal, and the mechanisms of action of their antioxidant effects were investigated. Subsequent in vivo studies can be targeted using molecules with the greatest probability of success. (C) 2009 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts

Rubika Balendra, Ashley R. Jones, Ahmad Al Khleifat, Theresa Chiwera, Paul Wicks, Carolyn A. Young, Pamela J. Shaw, Martin R. Turner, P. Nigel Leigh, Ammar Al-Chalabi

Summary: ALS is a clinically heterogeneous disease and the King's clinical staging system has been proposed to aid in patient care, research, trial design and health economic analyses. This study validates the King's clinical staging system in four patient groups located in different regions and countries, demonstrating consistent results.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis

Ozlem Yildiz, Johannes Schroth, Timothy Tree, Martin R. Turner, Pamela J. Shaw, Sian M. Henson, Andrea Malaspina

Summary: In this study, researchers found that aging exacerbates neuroinflammation and older age is associated with a worse prognosis in ALS. They also discovered activation of cell senescence pathways and increase of proinflammatory cytokines in ALS patients. The findings suggest that lymphocyte senescence and memory state may play a central role in the progression of ALS.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Biology

Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication

Tobias Moll, Valerie Odon, Calum Harvey, Mark O. Collins, Andrew Peden, John Franklin, Emily Graves, Jack N. G. Marshall, Cleide dos Santos Souza, Sai Zhang, Lydia Castelli, Guillaume Hautbergue, Mimoun Azzouz, David Gordon, Nevan Krogan, Laura Ferraiuolo, Michael P. Snyder, Pamela J. Shaw, Jan Rehwinkel, Johnathan Cooper-Knock

Summary: This study identifies a link between reduced expression of EXOSC2 and reduced SARS-CoV-2 replication. Increased expression of EXOSC2 is associated with higher risk of clinical COVID-19. The study also reveals interaction between the SARS-CoV-2 RNA polymerase and most of the human RNA exosome components.

LIFE SCIENCE ALLIANCE (2023)

Article Clinical Neurology

Analysis of brain and spinal MRI measures in a common domain to investigate directional neurodegeneration in motor neuron disease

C. Toh, A. Keslake, T. Payne, A. Onwuegbuzie, J. Harding, K. Baster, N. Hoggard, P. J. Shaw, I. D. Wilkinson, T. M. Jenkins

Summary: This study analyzed MRI data of the brain and cervical spinal cord to investigate pathophysiological hypotheses in vivo. A cranio-caudal step-change in MND patients was observed, which requires further investigation in larger cohorts.

JOURNAL OF NEUROLOGY (2023)

Article Spectroscopy

Non-negative matrix factorisation of Raman spectra finds common patterns relating to neuromuscular disease across differing equipment configurations, preclinical models and human tissue

James J. P. Alix, Maria Plesia, Chloe N. Schooling, Alexander P. Dudgeon, Catherine A. Kendall, Visakan Kadirkamanathan, Christopher J. McDermott, Grainne S. Gorman, Robert W. Taylor, Richard J. Mead, Pamela J. Shaw, John C. Day

Summary: Raman spectroscopy shows promise as a biomarker for neuromuscular diseases. Challenges include sensitivity to instrument configurations, translation across tissues, and development of analytics for disease identification. Nonnegative matrix factorisation (NMF) was used to analyse Raman spectra from different clinical and preclinical settings, accurately identifying disease states. NMF decomposition enhances the potential of Raman spectroscopy for studying fatal neuromuscular diseases.

JOURNAL OF RAMAN SPECTROSCOPY (2023)

Review Biotechnology & Applied Microbiology

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation

Richard J. Mead, Ning Shan, H. Joseph Reiser, Fiona Marshall, Pamela J. Shaw

Summary: Amyotrophic lateral sclerosis (ALS) is a devastating disease with degeneration of motor neurons. Despite the challenges, ALS has seen progress in the development of disease-modifying therapies. Significant advancements have been made in ALS research and novel therapeutic approaches are being applied to address unmet medical needs. This review discusses how advanced knowledge and new approaches can lead to effective translation of therapies for ALS and potentially impact drug discovery for neurodegenerative disorders.

NATURE REVIEWS DRUG DISCOVERY (2023)

Review Clinical Neurology

Prospects for gene replacement therapies in amyotrophic lateral sclerosis

Ilaria Giovannelli, Adrian Higginbottom, Janine Kirby, Mimoun Azzouz, Pamela J. Shaw

Summary: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by the progressive loss of motor neurons. Recent advances in genetic therapy offer new opportunities for treating ALS, although there are still challenges to overcome.

NATURE REVIEWS NEUROLOGY (2023)

Review Clinical Neurology

Physical activity as an exogenous risk factor for amyotrophic lateral sclerosis: a review of the evidence

Laura Chapman, Johnathan Cooper-Knock, Pamela J. Shaw

Summary: Chapman et al. reviewed published evidence on the link between strenuous physical activity and the development of ALS. The consensus supports physical activity as a risk factor for ALS, with genetic susceptibility also playing a role.
Article Neurosciences

The contribution of Neanderthal introgression and natural selection to neurodegenerative diseases

Zhongbo Chen, Regina H. Reynolds, Antonio F. Pardinas, Sarah A. Gagliano Taliun, Wouter van Rheenen, Kuang Lin, Aleksey Shatunov, Emil K. Gustavsson, Isabella Fogh, Ashley R. Jones, Wim Robberecht, Philippe Corcia, Adriano Chio, Pamela J. Shaw, Karen E. Morrison, Jan H. Veldink, Leonard H. van den Berg, Christopher E. Shaw, John F. Powell, Vincenzo Silani, John A. Hardy, Henry Houlden, Michael J. Owen, Martin R. Turner, Mina Ryten, Ammar Al-Chalabi

Summary: This study found that Neanderthal DNA introgression does not contribute to the genetic risk of neurodegenerative disorders in anatomically-modern humans. Additionally, there is no evidence to support the idea that common variants associated with these disorders are maintained by natural selection. These findings provide valuable insights into the origins of neurodegenerative diseases and address longstanding debates.

NEUROBIOLOGY OF DISEASE (2023)

Article Cell Biology

A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export reduces the neurotoxic effects of dipeptide repeat proteins

Lydia M. Castelli, Ya-Hui Lin, Alvaro Sanchez-Martinez, Aytac Gul, Kamallia Mohd Imran, Adrian Higginbottom, Santosh Kumar Upadhyay, Nora M. Markus, Raquel Rua Martins, Johnathan Cooper-Knock, Claire Montmasson, Rebecca Cohen, Amy Walton, Claudia S. Bauer, Kurt J. De Vos, Richard J. Mead, Mimoun Azzouz, Cyril Dominguez, Laura Ferraiuolo, Pamela J. Shaw, Alexander J. Whitworth, Guillaume M. Hautbergue

Summary: Hexanucleotide repeat expansions in C9ORF72 are a common genetic cause of familial ALS and FTD. These expansions result in the translation of neurotoxic DPRs that contribute to neurodegeneration. A cell-penetrant peptide was found to block the export and translation of C9ORF72-repeat transcripts and toxic DPRs, leading to improved survival of ALS motor neurons and decreased DPR expression in animal models. Disrupting DPR production may be a potential strategy to ameliorate neurodegeneration in ALS/FTD.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Neurosciences

Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival

Brett N. Adey, Johnathan Cooper-Knock, Ahmad Al Khleifat, Isabella Fogh, Philip van Damme, Philippe Corcia, Philippe Couratier, Orla Hardiman, Russell McLaughlin, Marc Gotkine, Vivian Drory, Vincenzo Silani, Nicola Ticozzi, Jan H. Veldink, Leonard H. van den Berg, Mamede de Carvalho, Susana Pinto, Jesus S. Mora S. Pardina, Monica Povedano Panades, Peter M. Andersen, Markus Weber, Nazli A. Basak, Christopher E. Shaw, Pamela J. Shaw, Karen E. Morrison, John E. Landers, Jonathan D. Glass, Patrick Vourc'h, Richard J. B. Dobson, Gerome Breen, Ammar Al-Chalabi, Ashley R. Jones, Alfredo Iacoangeli

Summary: This study explores the relationship between CAV1/2 genes and ALS. The expression of CAV1 and CAV2 genes is found to be higher in ALS patients compared to controls, and carriers of CAV1/2 enhancer mutations show improved survival and slower progression of the disease.

FRONTIERS IN CELLULAR NEUROSCIENCE (2023)

Article Clinical Neurology

Combining electromyography and Raman spectroscopy: optical EMG

James J. P. Alix, Maria Plesia, Pamela J. Shaw, Richard J. Mead, John C. C. Day

Summary: Optical EMG, combining EMG and Raman spectroscopy, can provide both electrophysiological and molecular data during a single needle insertion, offering potential diagnostic information for neuromuscular diseases. The experimental results demonstrate that optical EMG can detect specific muscle activation and identify molecular composition differences in diseased muscle through Raman spectra.

MUSCLE & NERVE (2023)

Correction Biochemistry & Molecular Biology

miR-196a provides antioxidative neuroprotection via USP15/Nrf2 regulation in Huntington's disease (vol 209, pg 292, 2023)

Siew Chin Chan, Chih-Wei Tung, Chia-Wei Lin, Yun-Shiuan Tung, Po-Min Wu, Pei-Hsun Cheng, Chuan-Mu Chen, Shang-Hsun Yang

FREE RADICAL BIOLOGY AND MEDICINE (2024)

Article Biochemistry & Molecular Biology

Ribosome-targeting antibiotic control NLRP3-mediated inflammation by inhibiting mitochondrial DNA synthesis

Suyuan Liu, Meiling Tan, Jiangxue Cai, Chenxuan Li, Miaoxin Yang, Xiaoxiao Sun, Bin He

Summary: This study reveals that the antibiotic doxycycline effectively inhibits NLRP3 inflammasome activation by targeting mitochondrial translation and mtDNA synthesis, offering potential for the treatment of NLRP3-related diseases.

FREE RADICAL BIOLOGY AND MEDICINE (2024)

Article Biochemistry & Molecular Biology

Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M

Hao Liu, Nana Li, Ge Kuang, Xia Gong, Ting Wang, Jun Hu, Hui Du, Minxuan Zhong, Jiashi Guo, Yao Xie, Yang Xiang, Shengwang Wu, Yiling Yuan, Xinru Yin, Jingyuan Wan, Ke Li

Summary: Protectin D1 (PTD1) improves hepatic steatosis, inflammation and fibrosis in a NASH mouse model by inhibiting the activation of TLR4 downstream signaling pathway, possibly through upregulation of IRAK-M expression, suggesting a potential new treatment for NASH.

FREE RADICAL BIOLOGY AND MEDICINE (2024)